Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Takayasu Arteritis Clinical Trial

Official title:

Comparison of the Efficacy and Safety of Tofacitinib and Methotrexate Based on Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05102448
• Other study ID #: TACTIC-TM
• Status: Recruiting
• Phase: Phase 4
• Start date: November 1, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2021
• Source: Shanghai Zhongshan Hospital
• Contact: Lindi Jiang, Ph.D., M.D.
• Phone: 021-64041990
• Email: zsh-rheum[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to evaluate and compare the efficacy and safety of tofacitinib and methotrexate based on prednisone therapy in patients with Takayasu arteritis

Description:

Takayasu's arteritis (TAK), a chronic large vessel vasculitis, involves the aorta and its main branches. Glucocorticoids and immunosuppressants such as methotrexate, cyclophosphamide are common agents for TAK treatment. However, their effects for remission induction and relapse prevention are not satisfied. More effective agents for TAK treatment remain to be investigated. Tofacitinib (TOF) is a Jak inhibitor, which has been proved to be effective in multiple autoimmune diseases such as rheumatoid arthritis. Our preliminary real-world study also demonstrated a promising treatment effect of TOF in patients with TAK. But its efficacy and safety needs further verification. The present randomized controlled trial aimes to compare efficacy between methotrexate and tofacitinib in TAK treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 76
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Patients met 1990 American College of Rheumatology (ACR) classification criteria or 2018 ACR classification criteria (draft) of TAK

2. Women or men aged 18-65

3. All patients agreed that there is no fertility plan during clinical trials, and the results of female serum or urinary pregnancy tests must be negative

4. Active TAK patients according to NIH disease activity criteria

5. All patients agreed to sign the informed consent

Exclusion Criteria:

1. Patients with organ failure who accord to one or more of the following conditions:

I.Heart function New York class 4 II.Glomerular filtration rate = 60ml/min III.Liver function Child grade 2 and above IV.High-frequency melanoma (attacks for 3 consecutive days) V.Acute cerebral infarction or cerebral hemorrhage VI.Blood pressure > 160/100mmHg

2. Patients who received revascularization surgery related to the treatment of TAK within 3 months (except balloon dilatation); balloon dilatation or surgery unrelated to TAK within 1 month

3. Patients who have other autoimmune diseases (e.g. ANCA-associated vasculitis, systemic lupus erythematosus, Behcet's disease, etc.)

4. Patients with severe, progressive or uncontrolled comorbidities of kidney, liver, blood system, gastrointestinal, lung, heart, etc or other coexisting medical conditions that may exert unexpected risks

5. Patients with concomitant diseases, such as asthma, that may require additional medium to high doses of glucocorticoids (prednisone = 10mg/ days or equivalent dose) during the study period

6. Patients with active infections with HBV, HCV, tuberculosis or other serious acute or chronic infections

7. Patients with malignancies

8. Patients with one or more of the following abnormal laboratory examinations I.Serum ALT or AST = 1.5 times the normal upper limit; II.White blood cell count = 4 × 109/L III.Platelet count = 100x109/L IV.Hemoglobin < 85g/L V.Other abnormal laboratory tests that may cause unacceptable risks

9. Patients allergic to the experimental drug

10. Patients who have ever failed to tofacitinib or methotrexate after 3 months' treatment in previous medical history

Related Conditions & MeSH terms

• Arteritis
• Takayasu Arteritis

Intervention

Drug:
• Tofacitinib
Tofacitinib 5mg twice a day for 12 months; Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until disuse if patients were in inactive status based on the NIH disease activity criteria.
• Methotrexate
Methotrexate (15mg each week) for 12 months Basic treatment with prednisone: (1) the initial dose of prednisone (or equivalent): 0.8mg/kg/day. (2) Glucocorticoids tapering: glucocorticoids is tapered after two weeks treatment and is tapered 5mg each 2 weeks to 10mg qd in the first 6 months if patients were in inactive status based on the NIH disease activity criteria. During the 6th to 12th month, glucocorticoids is tapered 2.5mg each 4 weeks until disuse if patients were in inactive status based on the NIH disease activity criteria.

Locations

Country	Name	City	State
China	Lindi Jiang	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effectiveness rate after 6 months' treatment	The effectiveness rate equals to patients who achieved this goal /patients at the end of 6 months. The effectiveness was defined as satisfying three of the following 1)-4) criteria and the 5) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging; 5) GCs is tapered to 10mg qd and this dosage is maintained for 4 weeks.	From the enrollment to the end of 6 months
Secondary	The remission rate with GCs 5mg qd at the end of 12 months	Ratio of patients who achieved remission with GCs 5mg qd at the end of 12 months. The remission is defined as satisfying three of the following 1)-4) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging. It is required that GCs 5mg qd should be maintained at least for four weeks.	From the enrollment to the the end of 12 months
Secondary	The remission rate with GCs 0mg qd at the end of 12 months	Ratio of patients who achieved remission with GCs 0mg qd at the end of 12 months. The remission is defined as satisfying three of the following 1)-4) criteria: 1) no systemic symptoms such as weakness, weight loss, etc; 2) no new ischemic symptoms or signs; 3) normal erythrocyte sedimentation rate (ESR); 4) no new vascular progression or new lesions upon imaging. It is required that GCs 0mg qd should be maintained at least for four weeks.	From the enrollment to the the end of 12 months
Secondary	Relapse free survival rate	Ratio of patients without relapse after achieving remission during the 12 months follow-up	From the enrollment to the the end of 12 month
Secondary	The cumulative dosage of GCs during the whole period of 12-months follow-up	The cumulative dosage = Sum of doses of prednisone (or equivalents) each day	From the enrollment to the the end of 12 months
Secondary	Side effects rate	Ratio of patients with side effects. All the kinds of adverse event related to the treatment and the disease itself will be recorded.	From the enrollment to the the end of 12 months